

Cord blood-derived CD34⁺ hematopoietic cells with low mitochondrial mass are enriched in hematopoietic repopulating stem cell function

Damia Romero-Moya,¹ Clara Bueno,¹ Rosa Montes,¹ Oscar Navarro-Montero,¹ Francisco J. Iborra,² Luis Carlos López,³ Miguel Martín,¹ and Pablo Menendez^{1,4,5}

¹GENyO (Centre for Genomics and Oncological Research: Pfizer / University of Granada /Andalusian Government), Granada;

²Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid; ³Centro de Investigación Biomédica, Instituto de Biotecnología, Universidad de Granada; ⁴Josep Carreras Leukemia Research Institute, Barcelona; and ⁵Institucion Catalana de Reserca i Estudis Avançats, (ICREA), Barcelona, Spain

ABSTRACT

The homeostasis of the hematopoietic stem/progenitor cell pool relies on a fine-tuned balance between self-renewal, differentiation and proliferation. Recent studies have proposed that mitochondria regulate these processes. Although recent work has contributed to understanding the role of mitochondria during stem cell differentiation, it remains unclear whether the mitochondrial content/function affects human hematopoietic stem *versus* progenitor function. We found that mitochondrial mass correlates strongly with mitochondrial membrane potential in CD34⁺ hematopoietic stem/progenitor cells. We, therefore, sorted cord blood CD34⁺ cells on the basis of their mitochondrial mass and analyzed the *in vitro* homeostasis and clonogenic potential as well as the *in vivo* repopulating potential of CD34⁺ cells with high (CD34⁺ Mito^{High}) *versus* low (CD34⁺ Mito^{Low}) mitochondrial mass. The CD34⁺ Mito^{Low} fraction contained 6-fold more CD34⁺CD38⁻ primitive cells and was enriched in hematopoietic stem cell function, as demonstrated by its significantly greater hematopoietic reconstitution potential in immunodeficient mice. In contrast, the CD34⁺ Mito^{High} fraction was more enriched in hematopoietic progenitor function with higher *in vitro* clonogenic capacity. *In vitro* differentiation of CD34⁺ Mito^{Low} cells was significantly delayed as compared to that of CD34⁺ Mito^{High} cells. The eventual complete differentiation of CD34⁺ Mito^{Low} cells, which coincided with a robust expansion of the CD34⁻ differentiated progeny, was accompanied by mitochondrial adaptation, as shown by significant increases in ATP production and expression of the mitochondrial genes ND1 and COX2. In conclusion, cord blood CD34⁺ cells with low levels of mitochondrial mass are enriched in hematopoietic repopulating stem cell function whereas high levels of mitochondrial mass identify hematopoietic progenitors. A mitochondrial response underlies hematopoietic stem/progenitor cell differentiation and proliferation of lineage-committed CD34⁻ cells.

Introduction

Human hematopoietic stem cells (HSC) and hematopoietic progenitor cells (HPC) are almost exclusively enriched in the CD34⁺ fraction, which represents a rare cell subset (<1%) in cord blood, bone marrow and mobilized peripheral blood.^{1,2} In the setting of clinical transplantation, the dose of total CD34⁺ cells infused per kilogram of patient's bodyweight is used as a predictor of short-term hematopoietic recovery and establishment of long-term engraftment.^{1,3,4} Although distinct surface markers (CD38, CD90, CD45RA, CD133, etc.)⁵ have been experimentally used to distinguish between HSC or HPC, *bona fide* segregation of HSC and HPC relies on *in vitro* and *in vivo* functional assays.

It has been extensively demonstrated that the CD34⁺ fraction is phenotypically and functionally heterogeneous. Experimentally, only 1:10 to 1:4 of CD34⁺ or CD34⁺CD38⁻ cells display clonogenic potential. Clinically, different outcomes/hematopoietic recovery are reported in patients with identical underlying disease who undergo hematopoietic stem/progenitor cell (HSPC) transplantation with equal doses

of CD34⁺ cells after receiving identical chemotherapy treatment. It can, therefore, be speculated that genetically identical CD34⁺ cells within the graft may exhibit cell-to-cell variations not only in the amount of individual gene products but also in metabolic homeostasis/mitochondrial status, resulting in phenotypic and functional diversity.⁶ The metabolic status of HSC and HPC becomes crucial during clinical HSPC transplantation since the efficiency of donor-derived HSC/HPC to engraft, survive, home, proliferate and differentiate into multiple lineages in a chemotherapy-induced aplastic patient is markedly influenced by their hypoxic niche, demanding a significant metabolic adaptation to survive and promote rapid and stable hematopoietic reconstitution in chemotherapy-induced aplastic microenvironments.^{7,8}

As in other tissues, mitochondria play key roles in HSC/HPC and have recently come under increased scrutiny because compelling evidence has revealed their role in numerous cellular processes, beyond ATP production and apoptosis regulation, and they have recently even been suggested to act as cell-fate or lineage determinants.⁹⁻¹¹ In fact, deregulation of mitochondrial function plays a pathophysio-

©2013 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2012.079244

The online version of this article has a Supplementary Appendix.

*These authors contributed equally to this work

Manuscript received on October 11, 2012. Manuscript accepted on January 9, 2013.

Correspondence: pablo.menendez@genyo.es

logical role in a range of hematologic diseases, such as inherited dyserythropoiesis, sideroblastic anemias and low-grade myelodysplastic syndromes.^{8,12} In addition, transcriptome, epigenetic and proteomic studies in stem cell systems have indicated that specific metabolic/mitochondrial properties are essential for regulating the balance between self-renewal and differentiation.^{13,14}

Although recent work has begun to shed light on the mitochondrial response during murine stem cell differentiation,^{7,10,15,16} how and to what extent the mitochondrial mass/function contributes to human hematopoietic stem and progenitor function remains poorly understood. Here, we found that mitochondrial mass correlates strongly with mitochondrial membrane potential ($\Delta\Psi_m$). This led us to separate cord blood-derived CD34⁺ cells based on their mitochondrial mass and to analyze the *in vitro* homeostasis and clonogenic potential as well as the *in vivo* repopulating potential of CD34⁺ cells with high (CD34⁺ Mito^{high}) versus low (CD34⁺ Mito^{low}) mitochondrial mass.

Design and Methods

Cord blood collection and CD34⁺ cell isolation and culture

Fresh umbilical cord blood units from healthy neonates were obtained from local hospitals following approval from our local Ethics and Biohazard Board Committee. The cord blood samples were pooled to reduce variability among individual units. Mononuclear cells were isolated using Ficoll-Hypaque and after lysing the red cells (Cytognos, Salamanca, Spain), CD34⁺ cells were purified by magnetic bead separation using the human CD34 MicroBead kit and the AutoMACS Pro separator (Miltenyi Biotec) as instructed by the manufacturer.¹⁷⁻¹⁹ The purity of the CD34⁺ fraction was assessed by flow cytometry using an anti-CD34-PE antibody (Miltenyi Biotec), and only CD34⁺ fractions showing purity higher than 90% were used.¹⁷⁻¹⁹ The CD34⁺ fraction was irradiated (15 Gy) and used as accessory cells for co-transplantation with CD34⁺ cells.

MitoTracker staining and cell sorting

CD34⁺ cells were stained with MitoTracker Red (CMXRos) and MitoTracker Green FM dye (Molecular Probes) for 10 min and 20 min, respectively, according to the manufacturer's guidelines and analyzed by wide confocal cytometry.⁶ For functional assays, CD34⁺ cells were FACS-sorted (FACSARIA-II, BD Biosciences) based on MitoTracker Green levels into CD34⁺ Mito^{high} and CD34⁺ Mito^{low} (n=10).

Measurements of ATP and reactive oxygen species

ATP levels were measured using a Cell-Titer-Glo[®] Luminescent Cell Viability Assay (Promega) according to the manufacturer's guidelines. Briefly, equal numbers of cells (5x10⁴/100 μ L) were seeded in a 96-well plate and 100 μ L of the reaction reagent were added to each well. After 10 min of shaking, the luminescence signal was detected using the GloMax[®]-Multi Detection System (Promega) and compared against the ATP Standard Curve using ATP disodium salt (Promega).⁶

Reactive oxygen species were measured using the mitochondrial superoxide indicator MitoSOX Red, as previously described.²⁰ Briefly, CD34⁺ Mito^{low} and CD34⁺ Mito^{high} cells were treated with 3 μ M MitoSOX for 20 min and were then washed twice in Hanks balanced salt solution and analyzed by flow cytometry (*Online Supplementary Figure S1A*).

Gene expression by quantitative reverse transcriptase polymerase chain reaction analysis

RNA was extracted using the All Prep DNA/RNA kit (Qiagen) and cDNA was synthesized by using SuperScript[™] First-Strand Synthesis System for reverse transcriptase polymerase chain reaction (Invitrogen). The expression of the mitochondrial genes ND1 and COX2 as well as HIF-1 α and Meis1 was compared between CD34⁺ Mito^{high} and CD34⁺ Mito^{low} cellular fractions by quantitative polymerase chain reaction analysis. Values were normalized to β -actin. The primers used were: ND1-Fw-5'-TGC-GAGCAGTAGCCCAAACAATCT-3', ND1-Rw-5'-TTATGGC-CAAGGGTCATGATGGCA-3', COX2-Fw-5'-ACAGATG-CAATCCCCGGACGTCTA-3', COX2-Rw-5'-GAC-GATGGGCATGAACTGTGGTT-3', HIF-1 α -Fw-5'-CTGCAACATGGAAGGTATTGCA-3', HIF-1 α -Rw-5'-TACCCACACT-GAGGTTGGTTACTG-3', Meis1-Fw-5'-AAAAGCGTCA-CAAAAAGCGT-3', Meis1-Rw-5'-GATGGTGAGTCCCGT-GTCTT-3', β -actin-Fw-5'-GATGGCCACGGCTGCTT-3' and β -actin-Rw-5'-AGGACTCCATGCCAGGAA-3'. The polymerase chain reaction conditions were 50°C for 2 min followed by 90°C for 10 min and 40 cycles of 95°C for 15 s and 60°C for 60 s.¹⁵ The expression of each gene was analyzed in three independent experiments performed in triplicate.

In vitro liquid culture, cell cycle, and apoptosis analyses of Mito^{high} and Mito^{low} CD34⁺ cells

FACS-sorted CD34⁺ Mito^{high} and CD34⁺ Mito^{low} cells were cultured for 40 days on StemSpan media (Stem Cell Technologies) supplemented with early hematopoietic cytokines [stem cell factor (100 ng/mL), FLT3L (100 ng/mL) and interleukin-3 (10 ng/mL); PeproTech].²¹ To determine the growth kinetics of Mito^{high} and Mito^{low} CD34⁺ cultures, cells were counted twice a week and replated at a density of 1x10⁵ cells/cm². Similarly, the maintenance of the CD34⁺ phenotype was analyzed twice a week as an approach to trace the "default" differentiation of both Mito^{high} and Mito^{low} CD34⁺ cells. For cell cycle analysis, Mito^{high} and Mito^{low} CD34⁺ cells were fixed in 70% ice-cold ethanol and stored at -20°C. Subsequently, cells were washed with ice-cold phosphate-buffered saline and suspended in propidium iodide buffer containing 5 μ g of propidium iodide and 100 μ g/mL of RNAase. Cell cycle distribution discriminating between quiescent cells (G0/G1) and cycling cells (S/G2/M phase) was analyzed on a FACSCanto-II cytometer using FACSDiva and ModFit software (BD Bioscience).²¹ The apoptotic status of Mito^{high} and Mito^{low} CD34⁺ cells was assessed using the annexin-V apoptosis detection kit (BD Biosciences) according to the manufacturer's instructions.²¹ Briefly, cells were harvested and washed twice with phosphate-buffered saline before staining with annexin V-phycoerythrin and 7-amino actinomycin D. Apoptotic cells were detected by gating the annexin V-positive fraction.²¹

Colony-forming unit assay

Primary human clonogenic progenitor assays (n=6) were performed by plating 1000 sorted CD34⁺ cells into methylcellulose H4434 (Stem Cell Technologies) containing the human growth factors stem cell factor (50 ng/mL), granulocyte-macrophage colony-stimulating factor (10 ng/mL), interleukin-3 (10 ng/mL) and erythropoietin (3 U/mL). Colonies were counted and scored on day 14 of the colony-forming unit (CFU) assay using standard morphological criteria.²¹ For secondary replating, all the CFU colonies from the primary methylcellulose culture were harvested, and a single-cell suspension was achieved, washed in Iscove's modified Dulbecco's medium and replated in the secondary CFU assay.

Mice transplantation and analysis of engraftment

NOD/LtSz-scid IL2R $\gamma^{-/-}$ mice (NSG) were housed under sterile conditions. The Animal Care Committee of the University of Granada approved all animal protocols (Ref. UGR-CEEA 2011-361). Mice (n=22) at 8 to 12 weeks of age were sublethally irradiated (2.5 Gy) for 6 to 12 h before transplantation. Mice were anesthetized by isoflurane inhalation, and intrabone marrow transplantation was performed as described in detail elsewhere.^{21,23} A total of 2×10^5 Mito^{high} or Mito^{low} CD34⁺ cells together with 5×10^4 irradiated accessory cells were transplanted in a volume of 30 μ L. For pain relief, 0.1 mg/kg buprenorphine and 5 mg/kg carprofen were administered immediately after transplantation and 24 h after.^{21,23} Mice were killed 7 weeks after transplantation. Cells from the bone marrow (injected tibia and from the contralateral tibia and femur), spleen, liver and peripheral blood were stained with anti-hHLA-ABC-FITC and anti-hCD45-APC-Cy7 (BD Biosciences) to analyze human chimerism by flow cytometry. All engrafted mice were assessed for multilineage analysis using anti-hCD33-PE for myeloid cells, anti-hCD19-APC for B cells, and anti-hCD34-PE-Cy7 for immature hematopoietic cells (BD Biosciences).^{21,22,24}

Statistical analysis

Data are expressed as mean \pm SD. Statistical comparisons were performed using a paired Student's t test. Differences were considered statistically significant when the *P* value was <0.05 .

Results

FACS sorting of CD34⁺ cells based on mitochondrial mass

We first analyzed by confocal cytometry the mitochondrial membrane potential ($\Delta\Psi$ m) and the mitochondrial mass using MitoTracker Red (CMXRos) and MitoTracker Green, respectively. A strong correlation was observed between mitochondrial mass and function ($\Delta\Psi$ m) in cord blood-derived CD34⁺ cells; the greater the mitochondrial content, the higher the $\Delta\Psi$ m (Figure 1A). Accordingly, CD34⁺ cells were FACS-sorted based on mitochondrial mass (MitoTracker Green) into CD34⁺ Mito^{High} and CD34⁺ Mito^{Low} (Figure 1B). Sorted CD34⁺ Mito^{High} contain 2-fold higher ATP levels (Figure 1C) and also express the mitochondrial-specific genes ND1 and COX2 at a level 2-fold higher than that of CD34⁺ Mito^{Low} (Figure 1D), confirming that CD34⁺ Mito^{High} cells have more expression of the mitochondrial-specific genes ND1 and COX2, and produce more ATP.

Hematopoietic stem versus progenitor cell characteristics of metabolically sorted cells

We next tested whether isolation of cord blood-derived CD34⁺ cells based solely on their mitochondrial mass enriches for stem and/or progenitor cell function. We utilized *in vitro* clonogenic CFU assays as a read-out for HPC function, and bone marrow xenotransplantation assays into NSG mice as an *in vivo* read-out for SCID-repopulating HSC function. Equal numbers of CD34⁺ Mito^{High} and CD34⁺ Mito^{Low} were plated in CFU assays and hematopoietic colonies were counted after 14 days. CD34⁺ Mito^{High} cells displayed higher clonogenic capacity in both primary and secondary CFU compared to CD34⁺ Mito^{Low} (Figure 2A). Scoring of the CFU revealed no differences in the CFU types (granulocyte-, macrophage-, granulocyte-macrophage-, erythroid- and mix-) obtained from CD34⁺

Mito^{High} versus CD34⁺ Mito^{Low}. These data suggest that the CD34⁺ Mito^{High} fraction is enriched in HPC.

In vivo hematopoietic reconstitution studies were undertaken to determine the long-term repopulating capacity of CD34⁺ Mito^{High} and CD34⁺ Mito^{Low}. Equal numbers of cells were transplanted into tibiae and mice were sacrificed 7 weeks later for chimerism analysis in multiple hematopoietic organs. Human chimerism was determined by flow cytometry using anti-CD45 and anti-HLA-ABC (Figure 2B). All engrafted mice were assessed for multilineage reconstitution using anti-CD19 (B cells), anti-CD33 (myeloid cells) and anti-CD34 (immature cells) (Figure 2B). The level of engraftment was higher in the mice transplanted with CD34⁺ Mito^{Low} than in those transplanted with CD34⁺ Mito^{High} regardless of the tissue analyzed, being more significant in the injected bone marrow (79 \pm 18% versus 59 \pm 17%; *P* <0.05 ; Figure 2C, left panel). We next characterized the engraftment composition, and found very similar multilineage composition in all tissues reconstituted with CD34⁺ Mito^{High} or CD34⁺ Mito^{Low} (Figure 2C, right panel) except for the more immature (CD45⁺CD34⁻) hematopoietic fraction which was significantly higher (15 \pm 3% versus 10 \pm 4%; *P* <0.05) in the bone marrow of mice engrafted with CD34⁺ Mito^{Low} cells.

The vast majority of CD34⁺ cells co-express the activation surface marker CD38 which is routinely associated with HPC whereas a very small proportion of CD34⁺ cells lack CD38 expression and are considered to be enriched in HSC.^{5,23,25} We, therefore, analyzed the proportion of CD34⁺CD38⁻ cells within the CD34⁺ Mito^{High} and CD34⁺ Mito^{Low} fractions (Figure 2D). The CD34⁺ Mito^{Low} fraction contained 6-fold higher numbers of CD34⁺CD38⁻ primitive cells, thus supporting the concept that the CD34⁺ Mito^{Low} fraction is enriched in repopulating HSC and also explaining, at least in part, the lower progenitor function of CD34⁺ Mito^{Low} cells (Figure 2A,C). Together, these data indicate that the CD34⁺ Mito^{Low} fraction is enriched in HSC function.

It has been reported¹⁶ recently that murine long-term HSC are highly enriched in HIF-1 α and Meis1. We, therefore, analyzed the expression of these factors on our CD34⁺ Mito^{High} and Mito^{Low} cells. As shown in *Online Supplementary Figure S1B*, both HIF-1 α and Meis1 were up-regulated, by 5- and 4-fold, respectively, in CD34⁺ Mito^{Low} cells as compared to in CD34⁺ Mito^{High} cells, confirming that these factors are robustly expressed in the CD34⁺ cell fraction enriched in repopulating stem cell function.

In vitro homeostasis of CD34⁺ Mito^{High} and CD34⁺ Mito^{Low} cells

It remains a challenge to expand CD34⁺ cells *in vitro* while retaining their stem/progenitor properties.²⁶ The homeostasis of sorted CD34⁺ Mito^{High} and CD34⁺ Mito^{Low} cells was analyzed *in vitro*. We first analyzed the *in vitro* differentiation kinetics of CD34⁺ Mito^{High} and CD34⁺ Mito^{Low} cultures by tracing the loss of the CD34 antigen. Interestingly, although the number of CD34⁺ cells diminished progressively over time, the differentiation of CD34⁺ Mito^{Low} cultures was significantly delayed as compared to that of CD34⁺ Mito^{High} (Figure 3A). After 15 days of liquid culture, CD34⁺ cells were no longer present in either CD34⁺ Mito^{High} or CD34⁺ Mito^{Low} cultures (Figure 3A,B). Expansion of CD34⁺ Mito^{High} and CD34⁺ Mito^{Low} cultures was moderate during the first 11-15 days of liquid culture (Figure 3B). However, coinciding with the complete differ-




Figure 1. Sorting of CD34⁺ cells according to mitochondrial content. (A) Correlation (arbitrary units) between mitochondrial function measured as mitochondrial $\Delta\Psi_m$ and mitochondrial mass (n=2). Mitotracker Red CMXRos and Mitotracker Green were used to measure mitochondrial $\Delta\Psi_m$ and mass, respectively. (B) Representative flow cytometry sorting of CD34⁺ cells according to the mitochondrial mass. Total CD34⁺ cells were stained with Mitotracker Green and sorted as Mito^{High} and Mito^{Low}. (C) Confirmation that sorted CD34⁺ Mito^{High} cells have significant more [ATP] (n=4). (D) Quantitative expression (ratio) of the mitochondrial ND1 and COX2 transcripts in CD34⁺ Mito^{High} versus CD34⁺ Mito^{Low} cells confirming almost double ND1 and COX2 expression levels in CD34⁺ Mito^{High} cells (n=4).

entiation (loss of CD34⁺ cells) of the CD34⁺ cultures after 11-15 days, the cell expansion of differentiated (CD34⁻) Mito^{High} and Mito^{Low} cultures was significantly boosted, especially in the cultures seeded with CD34⁺ Mito^{Low} cells (Figure 3B). After sorting, >99% of the CD34⁺ Mito^{Low} cells were quiescent (G0/G1 cell cycle phases) while ~20% of the CD34⁺ Mito^{High} cells were cycling (Figure 3C), but as CD34⁺ cells differentiated into CD34⁻ cells, Mito^{Low} cultures displayed a higher proportion of cycling cells (31 \pm 5% versus 22 \pm 6%, $P<0.05$) and lower apoptotic rate (21 \pm 3% versus 29 \pm 4%, $P<0.05$) than Mito^{High} cultures (Figure 3C,D), explaining the robust increased cell expansion of differentiated CD34⁻ Mito^{Low} cultures as compared to differentiated CD34⁻ Mito^{High} cultures (Figure 3B). Finally, the complete differentiation of CD34⁺ Mito^{Low} cultures by day 15 of liquid culture coupled with their robust expansion from day 15 onwards (Figure 3A,B) was accompanied by a mitochondrial adaptation, as demonstrated by a significant increase in energy (ATP) production (Figure 3E) and expression of the mitochondrial genes ND1 and COX2 (Figure 3F). This suggests that a mitochondrial response underlies the high proliferative activity of the CD34⁺ Mito^{Low}-differentiated derivatives.

Discussion

Mitochondria are multi-functional organelles that play a vital role in the cell, providing most of the cellular energy and regulating Ca²⁺ homeostasis, cell death, and differentiation; furthermore, they have recently been suggested to act as cell-fate or lineage determinants.⁹⁻¹¹ Hematopoietic

tissue homeostasis relies on a finely tuned balance between very dynamic intrinsically and extrinsically regulated processes of self-renewal, differentiation and proliferation. Based on recent transcriptomic, epigenomic and proteomic studies, it has been proposed that the cellular metabolism regulates these processes in different stem cell systems.¹⁴ The metabolic status of human HSC/HPC becomes crucial during clinical HSPC transplantation since the efficiency of donor-derived HSC/HPC to engraft, survive, home, proliferate and differentiate in chemotherapy-induced aplastic patients demands a significant metabolic adaptation to survive and promote rapid and stable hematopoietic reconstitution in chemotherapy-induced aplastic microenvironments.^{7,8} Furthermore, deregulation of mitochondrial functions plays a pathophysiological role in several hematologic diseases.^{8,12} Although recent work has begun to shed light on the mitochondrial response during stem cell differentiation,^{7,10,15,16} how, and to what extent the mitochondrial content affects human hematopoietic stem versus progenitor function remains elusive.

Here, we report that mitochondrial content correlates strongly with $\Delta\Psi_m$ in CD34⁺ cells. Thus, cord blood-derived CD34⁺ cells were sorted based solely on their mitochondrial mass, and the *in vitro* homeostasis and clonogenic potential as well as the *in vivo* repopulating potential of CD34⁺ cells with high (CD34⁺ Mito^{High}) versus low (CD34⁺ Mito^{Low}) mitochondrial content were analyzed. As expected, the ATP levels and expression of mitochondrial-specific genes were higher in CD34⁺ Mito^{High} than in CD34⁺ Mito^{Low} cells. We show for the first time in human CD34⁺ cells that hematopoietic stem and progeni-




Figure 2. Mito^{high} and Mito^{low} CD34⁺ cells display *in vitro* and *in vivo* functional differences. **(A)** Clonogenic (CFU) potential of Mito^{high} versus Mito^{low} CD34⁺ progenitor cells (n=6). Primary CFU cultures were harvested and re-plated in secondary CFU assays. **(B)** Representative flow cytometric analysis of human multi-lineage engraftment in NSG mice. Human cells were identified as HLA-ABC⁺ CD45⁺. Within the human graft, myeloid (CD33⁺), B-lymphoid (CD19⁺) and immature (CD34⁺) lineages were analyzed. **(C)** Levels of human multi-lineage chimerism in injected tibia (IT), contra-lateral tibia (CL), peripheral blood (PB), spleen and liver indicating successful migration of the human CD34⁺ cells from the injected tibia. Each dot/square represents an individual mouse and the horizontal line indicates the mean of each experimental condition. **(D)** Proportion of CD38⁺ primitive/stem cells within CD34⁺ Mito^{high} and CD34⁺ Mito^{low} fractions (bottom panel). The upper panel depicts a representative flow cytometry analysis of CD38 and CD34 staining.

tor cell functions segregate partially between metabolically sorted cells. The CD34⁺ Mito^{low} fraction displayed significantly higher *in vivo* reconstitution potential upon inoculation in NSG mice whereas the CD34⁺ Mito^{high} fraction was more enriched in progenitor function with higher *in vitro* clonogenic capacity. This is in line with the “dogma” that stem cells are usually quiescent and contain low numbers of mitochondria whereas progenitors are more proliferative and contain higher numbers of mitochondria.^{9,10} The vast majority of CD34⁺ cells co-express the activation surface marker CD38 which is associated with HPC whereas a very small proportion of CD34⁺ cells lack CD38 expression and are considered to be enriched in HSC.^{5,23,25} Accordingly, the proportion of CD34⁺CD38⁻ primitive cells was 6-fold higher in the CD34⁺ Mito^{low} than in the CD34⁺ Mito^{high} fraction, supporting the concept that the CD34⁺ Mito^{low} fraction is enriched in repopulating HSC function, and also explaining, at least in part, the lower

progenitor function of CD34⁺ Mito^{low} cells. Our data confirm previous findings in mice showing that the Mito^{low} cellular fraction of murine bone marrow is highly enriched in repopulating HSC, partially due to the enrichment of long-term HSC in this Mito^{low} fraction.¹⁶ Furthermore, Simsek *et al.*¹⁶ recently reported that murine long-term HSC are highly enriched in Meis1, a HSC-associated transcriptional factor required for definitive hematopoiesis, and in HIF-1 α , a master regulator of glycolysis and mitochondrial respiration, including a metabolic shift toward anaerobic glycolysis. In line with this study, the expression of both HIF-1 α and Meis1 was found to be robustly up-regulated in CD34⁺ Mito^{low} cells as compared to in CD34⁺ Mito^{high} cells, confirming that these factors are robustly expressed in the CD34⁺ cell fraction enriched in repopulating stem cell function. Interestingly, mitochondrial content enriches for either HSC or HPC but it does not seem to act as a determinant in progenitor/lineage com-




Figure 3. *In vitro* homeostasis of CD34⁺ Mito^{High} and CD34⁺ Mito^{Low} cells. (A) Loss of CD34 antigen over time in liquid cultures seeded with Mito^{High} versus Mito^{Low} CD34⁺ cells (n=6). (B) *In vitro* expansion of liquid cultures initially seeded with Mito^{High} versus Mito^{Low} CD34⁺ (n=6). Note that after day 15 there are no residual CD34⁺ cells in the culture. From day 15 onwards the entire culture is comprised of differentiated CD34⁺ cells (flow cytometry panel as inset). (n=6). (C) Proportion of cycling cells (S/G2/M cell cycle phase) measured at the indicated time points in Mito^{High} versus Mito^{Low} CD34⁺ cultures (n=2). (D) Proportion of apoptotic cells (annexin V⁺) measured at the indicated time points in Mito^{High} versus Mito^{Low} CD34⁺ cultures (n=2). (E-F) *In vitro* differentiation of CD34⁺ Mito^{Low} cultures (loss of CD34 antigen) is associated with increased ATP production (E) and higher levels of ND1 and COX2 expression (F).

mitment since the multilineage composition in both CFU and repopulating assays was very similar between CD34⁺ Mito^{High} and CD34⁺ Mito^{Low} cells. These data suggest that mitochondrial mass/activity determines global *in vitro* clonogenic potential and *in vivo* repopulating function but does not impair/skew normal developmental stem cell fate/hematopoietic lineage commitment.

Homeostasis of CD34⁺ Mito^{High} and CD34⁺ Mito^{Low} cultures was further analyzed *in vitro*. The differentiation of CD34⁺ Mito^{Low} cultures was significantly delayed as compared to that of CD34⁺ Mito^{High}, but CD34⁺ cells were no longer present in either CD34⁺ Mito^{High} or CD34⁺ Mito^{Low} cultures after 15 days. Expansion of CD34⁺ Mito^{High} and CD34⁺ Mito^{Low} cultures was limited during the first 15 days; however, coinciding with the complete differentiation of the CD34⁺ cultures after 15 days, the expansion of differentiated (CD34⁺) Mito^{High} and Mito^{Low} cells was significantly boosted, especially in the cultures seeded with CD34⁺ Mito^{Low} cells. The fact that the CD34⁺ Mito^{Low} cells display a delayed differentiation coupled to a much higher expan-

sion rate of their CD34⁺ differentiated cells supports the better hematopoietic engraftment of NSG mice transplanted with the CD34⁺ Mito^{Low} fraction because efficient *in vivo* hematopoietic reconstitution relies on a finely tuned balance between low proliferative/self-renewing CD34⁺ HSC and rapidly amplifying progenitors, many of which are far lineage-committed and lack CD34 expression.

Mitochondrial biogenesis during the differentiation of embryonic stem cells has recently been studied.^{11,27} Undifferentiated embryonic stem cells have a low mitochondrial content and low levels of ATP. Upon differentiation the mitochondrial content increases and mitochondrial biogenesis is activated to promote the synthesis of increased levels of ATP which seem to be required for the homeostasis of the differentiated cells.²⁸⁻³⁰ Similarly, we found that the complete differentiation of CD34⁺ Mito^{Low} cells, which coincided with a robust expansion of the differentiated progeny, was accompanied by mitochondrial adaptation as demonstrated by a significant increase in ATP production and expression of the mitochondrial

genes ND1 and COX2. This suggests that HSPC differentiation and proliferation of rapidly amplifying lineage-committed CD34⁺ cells are processes demanding up-regulation of mitochondrial content and biogenesis, and these properties seem to be conserved among embryonic stem cells and HSC/HPC.

Increased bioenergetics and mitochondrial activity come at an increased risk of oxidative damage, primarily in the form of reactive oxygen species (ROS) which are mainly generated by the mitochondria.^{10,51} Various recent studies in mice have provided evidence for a link between intracellular ROS levels and preservation of stem cell function, with increased levels of ROS being associated with reduced repopulating stem cell activity.^{52,53} Stem cells have strategies to lessen the negative impact of ROS such as lowering the numbers of mitochondria and ATP generation by promoting glycolysis over oxidative phosphorylation.^{29,34} In this study, human CD34⁺ Mito^{low} cells which were shown to be more enriched in HSC function displayed significantly lower levels of ROS than CD34⁺ Mito^{high} cells (Online Supplementary Figure S1A) which are more enriched in HPC function, suggesting that HSC function may be enriched in the CD34⁺ Mito^{low} fraction as a strategy to lessen the negative impact of ROS, which can induce cell damage/death. Finally, during mitosis mitochondria may be segregated to daughter cells either symmetrically or asymmetrically. Asymmetric cellular distri-

bution of mitochondria is a dynamic process which has been observed in some species and may play a role in cell-fate determination, differentiation and self-renewal.^{11,27,35-37}

Whether symmetric or asymmetric mitochondrial segregation occurs in human CD34⁺ cells is unknown. It would be worth studying in future work whether asymmetric mitochondrial segregation could be an underlying mechanism explaining why phenotypically identical CD34⁺ cells may exhibit cell-to-cell variations in mitochondrial content resulting in functional diversity.

Funding

This work was funded by the CICE/FEDER (P08-CTS-3678) de la Junta de Andalucía with a grant to PM, the FIS/FEDER (PI10/00449 to PM and PI11/00119 to CB), the MICINN (Fondo Especial del Estado para Dinamización de la Economía y Empleo/PLE-2009-0411) with a grant to PM, and the Foundation "Spanish Association Against Cancer"/Junta Provincial de Albacete (CI110023 to PM). DRM (PFIS scholarship FI11/0511), RM and CB (CP07/0059) are supported by the ISCIII. ON-M was supported by the Health of Department of the Junta de Andalucía.

Authorship and Disclosures

Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.

References

- Menendez P, Perez-Simon JA, Mateos MV, Caballero MD, Gonzalez M, San-Miguel JF, et al. Influence of the different CD34⁺ and CD34⁻ cell subsets infused on clinical outcome after non-myeloablative allogeneic peripheral blood transplantation from human leucocyte antigen-identical sibling donors. *Br J Haematol*. 2002;119(1):135-43.
- Sutherland DR, Keating A. The CD34 antigen: structure, biology, and potential clinical applications. *J Hematother*. 1992;1(2):115-29.
- Menendez P, Caballero MD, Prosper F, Del Canizo MC, Perez-Simon JA, Mateos MV, et al. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen. *Transfusion*. 2002;42(9):1159-72.
- Menendez P, Prosper F, Bueno C, Arbona C, San Miguel JF, Garcia-Conde J, et al. Sequential analysis of CD34⁺ and CD34⁻ cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plus G-CSF and cyclophosphamide. *Leukemia*. 2001;15(3):430-9.
- Menendez P, del Canizo MC, Orfao A. Immunophenotypic characteristics of PB-mobilised CD34⁺ hematopoietic progenitor cells. *J Biol Regul Homeost Agents*. 2001;15(1):53-61.
- das Neves RP, Jones NS, Andreu L, Gupta R, Enver T, Iborra FJ. Connecting variability in global transcription rate to mitochondrial variability. *PLoS Biol*. 2010;8(12):e1000560.
- Danet GH, Pan Y, Luongo JL, Bonnet DA, Simon MC. Expansion of human SCID-repopulating cells under hypoxic conditions. *J Clin Invest*. 2003;112(1):126-35.
- Fontenay M, Cathelin S, Amiot M, Gyan E, Solary E. Mitochondria in hematopoiesis and hematological diseases. *Oncogene*. 2006;25(34):4757-67.
- Inoue S, Noda S, Kashima K, Nakada K, Hayashi J, Miyoshi H. Mitochondrial respiration defects modulate differentiation but not proliferation of hematopoietic stem and progenitor cells. *FEBS Lett*. 2010;584(15):3402-9.
- Mantel C, Messina-Graham S, Broxmeyer HE. Upregulation of nascent mitochondrial biogenesis in mouse hematopoietic stem cells parallels upregulation of CD34 and loss of pluripotency: a potential strategy for reducing oxidative risk in stem cells. *Cell Cycle*. 2010;9(10):2008-17.
- Parker GC, Acsadi G, Brenner CA. Mitochondria: determinants of stem cell fate? *Stem Cells Dev*. 2009;18(6):803-6.
- Lyu BN, Ismailov SB, Ismailov B, Lyu MB. Mitochondrial concept of leukemogenesis: key role of oxygen-peroxide effects. *Theor Biol Med Model*. 2008;5:23.
- Macarthur BD, Ma'ayan A, Lemischka IR. Systems biology of stem cell fate and cellular reprogramming. *Nat Rev Mol Cell Biol*. 2009;10(10):672-81.
- Suda T, Takubo K, Semenza GL. Metabolic regulation of hematopoietic stem cells in the hypoxic niche. *Cell Stem Cell*. 2011;9(4):298-310.
- Ramos-Mejia V, Bueno C, Roldan M, Sanchez L, Ligerio G, Menendez P, et al. The adaptation of human embryonic stem cells to different feeder-free culture conditions is accompanied by a mitochondrial response. *Stem Cells Dev*. 2012;21(9):1549-58.
- Simsek T, Kocabas F, Zheng J, Deberardinis RJ, Mahmoud AI, Olson EN, et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. *Cell Stem Cell*. 2010;7(3):380-90.
- Bueno C, Catalina P, Melen GJ, Montes R, Sanchez L, Ligerio G, et al. Etoposide induces MLL rearrangements and other chromosomal abnormalities in human embryonic stem cells. *Carcinogenesis*. 2009;30(9):1628-37.
- Bueno C, Montes R, Martin L, Prat I, Hernandez MC, Orfao A, et al. NG2 antigen is expressed in CD34⁺ HPCs and plasmacytoid dendritic cell precursors: is NG2 expression in leukemia dependent on the target cell where leukemogenesis is triggered? *Leukemia*. 2008;22(8):1475-8.
- Bueno C, Montes R, Menendez P. The ROCK inhibitor Y-27632 negatively affects the expansion/survival of both fresh and cryopreserved cord blood-derived CD34⁺ hematopoietic progenitor cells. *Stem Cell Rev*. 2010;6(2):215-23.
- Bergamini C, Moruzzi N, Sblendido A, Lenaz G, Fato R. A water soluble CoQ10 formulation improves intracellular distribution and promotes mitochondrial respiration in cultured cells. *PLoS One*. 2012;7(3):e33712.
- Montes R, Ayllon V, Gutierrez-Aranda I, Prat I, Hernandez-Lamas MC, Ponce L, et al. Enforced expression of MLL-AF4 fusion in cord blood CD34⁺ cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia. *Blood*. 2011;117(18):4746-58.
- Bueno C, Montes R, de la Cueva T, Gutierrez-Aranda I, Menendez P. Intra-bone marrow transplantation of human CD34(+) cells into NOD/LtSz-scid IL-2rgamma(null)

- mice permits multilineage engraftment without previous irradiation. *Cytherapy*. 2010;12(1):45-9.
23. Levac K, Menendez P, Bhatia M. Intra-bone marrow transplantation facilitates pauciclonal human hematopoietic repopulation of NOD/SCID/beta2m(-/-) mice. *Exp Hematol*. 2005;33(11):1417-26.
 24. Navarro-Montero O, Romero-Moya D, Montes R, Ramos-Mejia V, Bueno C, Real PJ, et al. Intrahepatic transplantation of cord blood CD34⁺ cells into newborn NOD/SCID-IL2Rgamma(null) mice allows efficient multi-organ and multi-lineage hematopoietic engraftment without accessory cells. *Clin Immunol*. 2012;145(2):89-91.
 25. Terstappen LW, Huang S, Safford M, Lansdorp PM, Loken MR. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34⁺CD38⁻ progenitor cells. *Blood*. 1991; 77(6):1218-27.
 26. Lindemann A, Dorken B, Henschler R, Mertelsmann R, Herrmann F. Screening for expression of cytokines with hematopoietic growth factor activity by permanent human B-cell lines. *Leukemia* 1991;5(8):715-8.
 27. Facucho-Oliveira JM, St John JC. The relationship between pluripotency and mitochondrial DNA proliferation during early embryo development and embryonic stem cell differentiation. *Stem Cell Rev*. 2009; 5(2):140-58.
 28. Cho YM, Kwon S, Pak YK, Seol HW, Choi YM, Park do J, et al. Dynamic changes in mitochondrial biogenesis and antioxidant enzymes during the spontaneous differentiation of human embryonic stem cells. *Biochemical and biophysical research communications*. 2006;348(4):1472-8.
 29. Facucho-Oliveira JM, Alderson J, Spikings EC, Egginton S, St John JC. Mitochondrial DNA replication during differentiation of murine embryonic stem cells. *J Cell Sci*. 2007;120(22):4025-34.
 30. St John JC, Ramalho-Santos J, Gray HL, Petrosko F, Rawe VY, Navara CS, et al. The expression of mitochondrial DNA transcription factors during early cardiomyocyte in vitro differentiation from human embryonic stem cells. *Cloning Stem Cells*. 2005;7(3): 141-53.
 31. Morgan MJ, Kim YS, Liu ZG. TNFalpha and reactive oxygen species in necrotic cell death. *Cell Res*. 2008;18(3):343-9.
 32. Ito K, Hirao A, Arai F, Takubo K, Matsuoka S, Miyamoto K, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. *Nat Med*. 2006;12(4):446-51.
 33. Ito K, Hirao A, Arai F, Matsuoka S, Takubo K, Hamaguchi I, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. *Nature*. 2004;431(7011):997-1002.
 34. Jang YY, Sharkis SJ. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. *Blood*. 2007;110(8): 3056-63.
 35. Dinkelmann MV, Zhang H, Skop AR, White JG. SPD-3 is required for spindle alignment in *Caenorhabditis elegans* embryos and localizes to mitochondria. *Genetics*. 2007; 177(3):1609-20.
 36. Kruger N, Tolic-Norrelykke IM. Association of mitochondria with spindle poles facilitates spindle alignment. *Curr Biol*. 2008;18 (15):R646-R7.
 37. Staiber W. Asymmetric distribution of mitochondria and of spindle microtubules in opposite directions in differential mitosis of germ line cells in *Acricotopus*. *Cell Tiss Res*. 2007;329(1):197-203.